68 results
Page 3 of 4
8-K
EX-3.1
xxzjzpngu09jqn6
5 Jul 18
Material Modifications to Rights of Security Holders
4:03pm
S-1MEF
EX-8.1
61s6y1 oaisl4k5tdfiq
22 Jun 18
Registration of additional securities for an S-1
4:05pm
S-1MEF
EX-5.1
w0lx5kau67oh5bb9s9d6
22 Jun 18
Registration of additional securities for an S-1
4:05pm
424B4
iighyk54
15 Jun 18
Prospectus supplement with pricing info
12:26pm
FWP
rrpkbh6 pe9e0107nzvf
5 Jun 18
Free writing prospectus
4:31pm
10-KT
ptt0f9kl17y2dh7
26 Mar 18
Annual report (with FYE transition)
12:00am
424B5
bj79p54p
7 Oct 15
Prospectus supplement for primary offering
12:00am
8-K
EX-1.1
c4jr6 erlm5y
7 Oct 15
Contravir Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
12:00am
8-K
EX-10.1
bixt 7fx3kjljicu
15 Oct 14
ContraVir Pharmaceuticals Closes $9.0 Million Financing to Advance Lead Shingles Candidate
12:00am
10-K
b5ta145aqbhzfb
29 Sep 14
Annual report
12:00am
8-K
EX-10.1
ze0jx9lb78kayq
20 Mar 14
ContraVir Appoints James Sapirstein as Chief Executive Officer and Board Member
12:00am
10-12G/A
EX-99.1
jyc47 wb4
6 Feb 14
Registration of securities (amended)
12:00am
8-K
EX-10.1
hgh2a5s
5 Feb 14
Entry into a Material Definitive Agreement
12:00am
10-12G/A
EX-99.1
1b00sdicd1vnp
24 Dec 13
Registration of securities (amended)
12:00am